Malaysia: +603 2779 0098
The rising prevalence of NAFLD and NASH is leading to an increased burden on healthcare providers, as well as contributing to increased risk of developing end-stage liver disease or hepatocellular carcinoma. Whereas liver biopsy is still the gold standard for diagnosing NAFLD, in this presentation Ferenc Emil Mozes explores the potential of the new non-invasive imaging- and serum-based markers that have emerged in recent years.
Only products with same currency can be added to the basket. Clear the basket or finish the order, before adding products with another currency to the basket.
